Over the past decade, immunotherapy has rapidly changed the landscape of medicine, especially oncology. Checkpoint inhibitors and monoclonal antibodies capable of deploying the body's own immune functions against diseased cells have been heralded as a soon-to-be standard of care for cancer. The excitement around immunotherapy has been accompanied by impressive results, although some are tailored only to a limited number of patients and others are accompanied by substantial toxicity profiles. 1 Therefore, there are still unmet needs within the field. In this issue of Molceular Therapy, Rajagopalan et al. 2 performed a study aimed at using an aptamer-small interfering RNA (siRNA) conjugate to modulate the function and differentiation of activated CD8 + T cells.
Their work combines gene silencing, aptamer targeting, and immunomodulation to produce a therapeutic effect. Strategies such as the one used in this study may pave the way for more selective and effective control of therapeutic immunomodulation.
RNA interference (RNAi) technology has been steadily developing alongside immunotherapy but is not yet at the stage of market approval. This therapeutic strategy has great potential to target a variety of cellular functions with either short hairpin (shRNA) or siRNAs and can also produce immunomodulating effects by halting the expression of important signaling molecules. A major challenge of gene silencing is safe and efficient delivery of RNAi payloads to specific target cells. As a further obstacle, leukocytes are notoriously hard to transfect. [3] [4] [5] Recent advances in targeted delivery strategies for RNAi have mitigated some of the challenges, one example being the use of aptamers as targeting moieties.
Oligonucleotide aptamers can be either RNA or DNA based. The secondary and tertiary structures of aptamers allow them to recognize specific target molecules. They have found application in molecular sensors, inhibitors or activators, and targeting moieties. 6 Aptamers have become attractive targeting ligands due to their ease of production and low immunogenicity. The aptamer generation process comprises an extensive selection of oligonucleotide libraries for increasingly specific binding to the target molecule or cell. By conjugating a specific aptamer to siRNA, both targeting and therapeutic capabilities can be combined in a single small structure.
CD8
+ T cell differentiation is currently known to be mediated by the interaction of its surface CD25 receptors with interleukin 2 (IL-2). Binding of IL-2 results in differentiation into short-lived effector cells (SLECs), as opposed to memory precursor effector cells (MPECs). After eradicating antigenpresenting cells, SLECs undergo cell apoptosis, whereas MPECs can survive and recognize antigens again upon subsequent encounters. Rajagopalan et al. 2 designed a 4-1BB aptamer conjugated to an siRNA targeted to CD25 (siCD25) that binds to the 4-1BB receptor preferentially on CD8 + activated T cells to deliver siCD25. 4-1BB is a stimulatory receptor that is upregulated in activated T cells, promoting their survival and expansion. While activation of this 4-1BB receptor has a crucial role in influencing T cell function, the monovalent aptamer does not activate the 4-1BB signaling cascade. Previous work has indicated the requirement for 4-1BB to be cross-linked by a multivalent aptamer to induce receptor activation. 7 Hence, the monovalent nature of the 4-1BB aptamer selected here allows it to function solely as a siRNA targeting and delivery agent without target stimulation. The delivered siRNA leads to reduced CD25 expression, which impedes its interaction with IL-2, causing the CD8 + T cells to differentiate into MPECs instead of SLECs.
From a therapeutic perspective, the study showed modest indications of breast cancer tumor infiltration by the T cells and a reasonable increase in tumor susceptibility to secondary treatment implemented in parallel with the conjugate. The work by Rajagopalan et al. 2 exemplifies a successful approach of using an aptamer-based targeting moiety to deliver siRNAs and silence a receptor to modulate immune function (Figure 1) . Inducing cytotoxic T cell differentiation to MPECs yields a stronger prolonged immune response to antigen presenting cells. Additional investigation may demonstrate this avenue as a key advance in the immunotherapy field.
The use of aptamers is an exciting approach for targeting of siRNAs and, with the appropriate oligonucleotide structure, the binding affinity can be much higher than that afforded by immunoglobulin G (IgG) antibodies. 8 Unlike antibodies, the entire production process can be carried out using chemical synthesis. 9 Additionally, aptamersiRNA conjugates may have an advantage over conventional siRNA introduction because of their processing by Dicer substrates. 10 It has been demonstrated that shRNAs and RNA-aptamer conjugates must undergo cleavage within the cell by Dicer before they are suitable for gene silencing. This natural cleavage reaction within the cell allows for higher effectiveness in reaching and silencing the desired target gene.
An important concern with aptamers is the specificity of oligonucleotide candidates for the intended target. Aptamer selection is not at the standard of the protein engineering approach used for antibody selection. Additionally, it is laborious and time consuming. While SELEX and other technologies have become much more efficient in recent years, they still fail at times to produce aptamer candidates suitable for their intended purpose. 11 This gap in selection quality may be closed with new advances in bioinformatics, next-generation sequencing, improved chemistry, and stricter separation methods.
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Another challenge for aptamer development is to ensure retention of a stable and functional structure in vivo. RNA-based aptamers can exhibit greater structural diversity than their DNA-based counterparts, but they are exceptionally prone to degradation not only by natural alkaline hydrolysis, but also by nucleases. 6 While both RNAand DNA-based aptamers have a short circulation half-life, they can rapidly penetrate tissues to arrive at their target site because of their small size. 13 Nevertheless, it is unclear whether the delivery and clearance kinetics are favorable for controlling the release schedule of a therapeutic payload. Recent progress includes chemical modifications to the sugar moieties of the oligonucleotides and PEGylation to increase half-life in the body. 14, 15 The extraordinary potential of RNAi has, in turn, sparked efforts to discover more effective methods for delivery of these therapeutic nucleic acids. Antibody protamine conjugates and polymers are among some of the approaches. 16 One exciting strategy involves encapsulating siRNAs into protective nanoparticles that can be surface functionalized for cell-specific targeting in vivo. Recent studies have shown effective gene silencing using siRNA-loaded LNPs: one specific for anti-CD4 to target T lymphocytes and, more recently, anti-CD38 for B cell malignancies. 4, 5 Combinations of nanoparticlebased therapies with aptamer targeting are also being explored. 13 Rajagopalan and colleagues 2 execute a successful attempt in developing a target-specific aptamer without co-stimulatory effects, silencing of the desired target, and modulation of CD8 + T cell differentiation. Their work highlights the importance of selecting and tuning an aptamer that functions precisely. A plethora of additional studies are being done in the field to improve the technologies surrounding aptamer selection, specificity, and stability. This strategy may open new avenues in selective immunomodulation, which results in potent antitumor responses and might ultimately become a novel therapeutic modality in treating cancers. Upper path (with aptamer-siRNA conjugate) shows differentiation into MPECs, while the lower path (without aptamer-siRNA conjugate) shows differentiation into SLECs and eventual apoptosis.
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